Study of two chemotherapy drugs after surgery for uterine leiomyosarcoma
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial is testing a combination of two chemotherapy drugs (doxorubicin and trabectedin) given after surgery to prevent uterine leiomyosarcoma from coming back. The goal is to see if this treatment improves outcomes for patients with high-risk disease that has not spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of uterine leiomyosarcoma that has not spread beyond the uterus.
- You must have had surgery to remove all visible cancer within the past 3 months, with no signs of remaining disease on a recent CT scan.
- You should not have previously received chemotherapy for this cancer, and you should not have had radiation to the pelvic area.
- Your blood tests must show adequate kidney, liver, and bone marrow function.
- You must not have any serious uncontrolled medical conditions, such as heart disease or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether letrozole can help prevent uterine leiomyosarcoma from coming back after surgery. It focuses on people whose tumor shows estrogen receptor positivity.
This trial tests a combination of immunotherapy (atezolizumab), chemotherapy (doxorubicin), and radiation before and after surgery for people with high-risk soft tissue sarcoma in the arm, leg, or trunk. The goal is to see if this approach can improve outcomes.
This trial tests whether chemotherapy after surgery can help prevent uterine leiomyosarcoma from coming back in patients who are at high risk based on a genetic test of their tumor. It is for women with early-stage cancer (stage I) who have had complete surgery.
This Phase 2 trial studies how well gemcitabine or trabectedin works for people with leiomyosarcoma that cannot be fully removed or has spread. It’s for tumors that have grown or worsened despite prior standard chemotherapy.
This Phase 2 study tests a combination of three anti-cancer medicines to shrink or control leiomyosarcoma that cannot be fully removed by surgery or has spread. It may help people whose cancer has grown after prior treatment.
This trial is testing an experimental therapy against standard chemotherapy for people with endometrial cancer that has come back. The study looks for a certain protein (HER2) on cancer cells to decide which treatment group you may be in.
Hear when a new Uterine Leiomyosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.